SYBX

Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.

Wall Street analysts forecast SYBX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYBX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Synlogic Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Synlogic Inc. EPS for the last quarter amounts to -0.19 USD, increased 1800.00 % YoY.

Synlogic Inc (SYBX) has 1 emplpoyees as of December 15 2025.

Today SYBX has the market capitalization of 12.99M USD.